Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 5/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30487941 | 0.81 | TLR8 (0.44) | TLR8CYP1A2ESR1ESR2HSD17B1 | |
| SCHEMBL30487951 | 0.81 | TLR8 (0.44) | TLR8CYP1A2ESR1ESR2HSD17B1 | |
| SCHEMBL5608955 | 0.80 | ALDH1A1 (0.50) | CYP1A2SLC6A4 | |
| SCHEMBL4305920 | 0.79 | CYP1A2 (0.48) | TLR8CYP1A2ESR1ESR2HSD17B1 | |
| SCHEMBL8559405 | 0.75 | MT-CO2 (0.44) | TLR8POLBCLK1DYRK1ADYRK1B | |
| SCHEMBL21500880 | 0.75 | ESR1 (0.33) | TLR8CYP1A2ESR1ESR2HSD17B1 | |
| SCHEMBL27904877 | 0.73 | CLK1 (0.44) | TLR8CYP1A2ESR1ESR2POLB | |
| SCHEMBL10224689 | 0.73 | TSHR (0.50) | TLR8CYP1A2ESR1ESR2HSD17B1 | |
| SCHEMBL28325207 | 0.72 | AKR1B1 (0.46) | TLR8CLK1DYRK1ADYRK1B | |
| SCHEMBL3163561 | 0.72 | KDM4E (0.51) | TLR8CYP1A2ESR1ESR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, RET, ADK | TLR8 2048/4885CYP1A2 4682/4885ESR1 2928/4885 |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | DCK, RET, PRKCA | TLR8 2386/4885CYP1A2 4440/4885ESR1 3090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.